Pharma Mass Spectrometry Market

The pharma mass spectrometry market is projected to grow from USD 1.59 billion in 2025 to USD 2.75 billion by 2031, at a CAGR of 9.7% during this period.

The pharmaceutical mass spectrometry market is undergoing a fundamental shift owing to the patent cliff faced by branded pharma products, the rapid expansion of the manufacturing base of generics & APIs, and increased MS test volume among industrial & research pharma labs, which require advanced MS platforms with high-resolution capabilities, creating incremental demand for specialized MS infrastructure. Moreover, mass spectrometry is the preferred choice of technique/instrument owing to recent reforms by the US FDA that have created an explicit, non-negotiable requirement for LC-MS/MS-based analytical testing across all pharma drug development phases, establishing MS infrastructure as a regulatory compliance prerequisite rather than a discretionary investment. All such conditions are projected to grow the existing demand, which will help to grow the market for pharma mass spectrometry.

To know about the assumptions considered for the study download the pdf brochure

The competitive landscape is composed of several strong players that collectively hold a major share of the market. However, SMEs have a measurable position in the market. Noticeable players that operate in the pharma mass spectrometry market are Agilent Technologies, Inc. (US), Thermo Fisher Scientific, Inc. (US), Danaher Corporation (US), Waters Corporation (US), Bruker Corporation (US), Shimadzu Corporation (Japan), PerkinElmer, Inc (US)  Jeol, Ltd (Japan), Jasco (Japan), Teledyne Technologies Incorporated (US), and MKS Instruments (US), among others. The growth strategies employed by leading companies in this market include product approvals and launches, acquisitions, collaborations, partnerships, and strategic agreements. Over the past three years, product approvals and launches have been the most popular organic growth strategies adopted by market players seeking to increase their share of the market.

Agilent Technologies, Inc. (US)

Agilent Technologies offers a comprehensive portfolio of LC-MS, GC-MS, and ICP-MS in the mass spectrometry market. The company has a strong presence in North America and Europe. Over the last few years, the company has increased its R&D activities with a focus on investing a significant amount of its revenue and will continue to sustain its R&D expenditures to maintain its competitive position with a continuing flow of innovative, high-quality products and services. The company is also focusing on acquisitions, collaborations, and expansions to maintain its position in the market.

Thermo Fisher Scientific Inc. (US)

Thermo Fisher is a US-based company that offers a complete and integrated portfolio of solutions and services for laboratory research & analysis, healthcare & clinical science, manufacturing, and other fields. The company operates through four business segments, namely Analytical Instruments, Life Sciences Solutions, Specialty Diagnostics, and Laboratory Products & Services. The Analytical Instruments business segment offers mass spectrometry products. Thermo Fisher’s market leadership can be attributed to its extensive portfolio of mass spectrometry equipment. It focuses on expanding its product portfolio by introducing new and advanced mass spectrometers for customers in biotechnology, pharmaceuticals, toxicology, forensics, and other fields.

Waters Corporation (US)

Waters Corporation is among the prominent players in the mass spectrometry market. It specializes in liquid chromatography, mass spectrometry (MS), and thermal analysis systems, striving to advance scientific research worldwide. The company’s MS offerings cover all major types of analyzers, like quadrupole and ToF. Its MS portfolio includes technologies like QuanTof for high-resolution exact mass measurements, StepWave for trace component confirmation, Triwave for complex mixture characterization, and MS E for exact-mass ion spectra from samples. The company focuses on innovation, performance, and usability.

Market Ranking:

The pharma mass spectrometry market is moderately consolidated, with a limited group of global vendors capturing a significant share of revenue through broad instrument portfolios and entrenched installed bases. Thermo Fisher Scientific, Agilent Technologies, and Waters stand out as the principal participants, combining extensive LC-MS/MS product lines with pharma-grade software, assay packages, and service infrastructure that are embedded in pharmaceutical and biotech manufacturing settings worldwide. A second tier of manufacturers, including Shimadzu and Bruker, contributes to market supply through high-performance LC-MS and hybrid MS systems that are increasingly adapted for quality control and quality assurance workflows, often focusing on specific regions or niche applications.

Related Reports:

Pharma Mass Spectrometry Market by Component (Detector, Mass analyzer, Vacuum System), Product (Triple Quad, Q-ToF, FTMS, Quad), Application (Target ID, Bioanalysis, Mfg QA/QC, Impurity Testing), Installed Base & Replacement Rate - Global Forecasts to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com